Core Insights - Hanyu Pharmaceutical reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong financial performance [1] Financial Performance - The company's operating revenue for the first three quarters reached 683 million yuan, representing a year-on-year growth of 82.06% [1] - The net profit attributable to shareholders was 71.35 million yuan, showing a remarkable year-on-year increase of 305% [1]

证券代码：300199 证券简称：翰宇药业 公告编号：2025-057 深圳翰宇药业股份有限公司 关于变更公司高级管理人员暨调整 董事会提名委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于董事、副总裁兼董事会秘书辞职的情况 深圳翰宇药业股份有限公司（以下简称"翰宇药业"或"公司"）董事会于2025 年10月28日收到公司董事、副总裁兼董事会秘书杨笛女士提交的书面辞职报告。 杨笛女士因个人原因，向董事会提出辞去董事、副总裁、董事会秘书职务，原定 任期至第六届董事会届满之日止，辞去职务后杨笛女士将不再担任公司及子公司 任何职务。杨笛女士的辞职报告自送达公司董事会之日起生效。 李娉娉女士已取得深圳证券交易所颁发的《董事会秘书资格证书》，具备履 行职责所必需的专业能力，熟悉履职相关的法律法规，具备与岗位要求相适应的 职业操守及相应的专业胜任能力与从业经验，其任职符合《公司法》《深圳证券 交易所上市公司自律监管指引第2 号——创业板上市公司规范运作》等相关法律 和《公司章程》等规定。 李娉娉女士联系方式如下： 1、电话：0755-2658803 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-055 深圳翰宇药业股份有限公司 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 本次会议于 2025 年 10 月 28 日下午 15:30 在公司龙华总部 2006 董事会会议 室以现场结合通讯方式召开。会议应出席董事 9 人，实际出席会议董事 9 人，其 中董事 PINXIANG YU 女士、唐洋明先生、杨笛女士、独立董事胡文言先生、许 立勇先生以通讯表决方式出席会议。本次会议由董事长曾少贵先生召集和主持， 公司监事及高级管理人员列席了本次会议。 本次会议的召集、召开符合《中华人民共和国公司法》和《公司章程》的有 关规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司<2025年第三季度报告>的议案》； 经审核，董事会认为：编制和审核深圳翰宇药业股份有限公司 2025 年第三 季度报告的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 ...

Core Viewpoint - Han Yu Pharmaceutical (300199) reported a significant increase in revenue for the first three quarters of 2025, driven by a rise in formulation income, despite a net loss in the third quarter [1] Financial Performance - The company's third-quarter revenue reached 134 million yuan, marking an 11.86% year-on-year increase [1] - The net loss for the third quarter was 74.12 million yuan, compared to a loss of 24.44 million yuan in the same period last year [1] - For the first three quarters of 2025, total revenue was 683 million yuan, reflecting an 82.06% year-on-year growth [1] - The net profit for the first three quarters was 71.35 million yuan, a turnaround from a loss of 34.81 million yuan in the previous year [1] - Basic earnings per share for the first three quarters stood at 0.08 yuan [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥133,680,763.66, an increase of 11.86% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥74,117,132.91, a decrease of 203.18% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥72,551,040.34, down 114.31% from the previous year[5] - The company's operating income for the first nine months of 2025 was ¥683,122,870.45, representing an 82.06% increase compared to the same period in 2024[11] - Total operating revenue for the current period reached ¥683,122,870.45, a significant increase from ¥375,225,390.50 in the previous period, representing an increase of approximately 82%[24] - Net profit for the current period was ¥69,758,073.47, compared to a net loss of ¥35,828,756.23 in the previous period, marking a turnaround in profitability[25] - The total comprehensive income for the current period was ¥68,916,881.64, compared to a loss of ¥36,542,670.37 in the previous period, indicating a significant improvement[26] Assets and Liabilities - The total assets as of September 30, 2025, amounted to ¥3,170,646,772.12, reflecting a growth of 5.40% compared to the end of the previous year[5] - The company's total assets increased to ¥3,170,646,772.12 from ¥3,008,225,640.09, reflecting a growth of approximately 5.4%[22] - Total liabilities rose to ¥2,504,569,909.28 from ¥2,411,179,128.07, an increase of about 3.9%[22] - The equity attributable to shareholders of the parent company improved to ¥649,150,598.16 from ¥578,626,837.31, showing an increase of approximately 12.2%[22] Cash Flow - The operating cash flow net amount for the year-to-date was ¥270,699,175.19, an increase of 207.37% year-on-year[5] - Operating cash inflow for the current period reached ¥799,866,415.70, a significant increase from ¥501,843,341.73 in the previous period, representing a growth of approximately 58.9%[27] - Net cash flow from operating activities was ¥270,699,175.19, compared to ¥88,069,613.03 in the prior period, indicating a year-over-year increase of 207.5%[27] - The net increase in cash and cash equivalents for the current period was ¥24,473,569.69, contrasting with a decrease of -¥204,507,285.80 in the previous period[28] - The ending balance of cash and cash equivalents stood at ¥117,006,412.85, compared to ¥135,428,940.64 at the end of the previous period[28] Investments and Shareholder Information - The investment income for the first nine months of 2025 was ¥2,723,249.93, a significant increase of 614.25% year-on-year[12] - The company reported an investment income of ¥2,723,249.93, a recovery from a loss of ¥529,557.23 in the previous period[25] - The total number of common shareholders at the end of the reporting period is 110,118[15] - The largest shareholder, Zeng Shaogui, holds 11.16% of shares, amounting to 98,533,635 shares, with 41,190,000 shares pledged[15] - The top ten shareholders collectively hold significant stakes, with the top three being brothers and controlling shareholders of the company[16] Research and Development - Research and development expenses for the current period were ¥74,125,204.88, up from ¥59,329,000.15, indicating a growth of about 25%[24] Operational Changes and Approvals - The company signed a series of agreements with Sanofi on August 20, 2025, marking a new phase in the commercialization of their product[17] - The company received marketing approval for Acetate Atosiban Injection in Vietnam on August 22, 2025, expanding its overseas product pipeline[18] - The company and DS3 RX LLC mutually agreed to terminate their cooperation agreement, ending all unfulfilled obligations[18] Inventory and Current Assets - Total current assets rose to ¥565,088,980.79 from ¥463,048,006.84, indicating an increase of about 22.0%[20] - Inventory increased to ¥288,158,914.76 from ¥238,630,347.88, reflecting a growth of approximately 20.9%[20] Cash Flow from Activities - Cash outflow from investment activities totaled ¥173,272,458.81, up from ¥74,866,778.32, resulting in a net cash flow from investment activities of -¥165,492,033.13, worsening from -¥28,726,078.08[28] - Cash inflow from financing activities was ¥1,107,100,971.04, down from ¥1,241,333,185.23, while cash outflow from financing activities was ¥1,189,769,767.06, compared to ¥1,507,182,727.29 in the previous period[28] - The net cash flow from financing activities improved to -¥82,668,796.02 from -¥265,849,542.06, showing a reduction in cash outflow[28] Tax and Other Income - The company received ¥24,529,820.17 in tax refunds, significantly higher than ¥6,169,638.15 in the prior period, marking an increase of approximately 297.5%[27] - The company reported cash inflow from other operating activities of ¥133,946,814.91, up from ¥55,534,396.69, reflecting an increase of about 141.5%[27] - The company’s cash inflow from investment income was ¥3,288,131.02, a notable increase from ¥614,700.24 in the previous period[27]

Core Insights - The company, Shengnuo Biopharmaceuticals, reported significant growth in revenue and net profit for the first three quarters of 2025, primarily driven by increased overseas sales of GLP-1 class drugs, Semaglutide and Tirzepatide [1][2] - The company achieved a revenue of 520 million yuan, a year-on-year increase of 53.96%, and a net profit of 127 million yuan, reflecting a 123.03% increase [1] - The raw material drug business has become a major performance support for the company, with raw material revenue in the first half of the year reaching 189 million yuan, a 232.3% increase, accounting for approximately 55.92% of total revenue [1] Company Developments - Shengnuo Biopharmaceuticals is expanding its production capacity through various projects, including a new production line for peptide raw materials and technological upgrades for formulation industrialization [2] - The company’s raw materials are primarily sold overseas, and the expiration of patents for popular peptide drugs like Semaglutide in 2026 is expected to accelerate the penetration of generic drugs, leading to increased demand for peptide raw materials [2] Industry Context - The competition in the GLP-1 raw material drug market is intensifying, with several domestic companies such as Pro Pharmaceutical, Nuotai Biotech, and Hanyu Pharmaceutical also involved [2] - The market for oral peptide formulations is anticipated to drive higher demand for raw materials, presenting new growth opportunities for companies that strategically invest in this area [2] - The original manufacturer of Semaglutide, Novo Nordisk, has lowered its annual performance guidance, raising questions about the sustainability of the current market dynamics [2]

Group 1 - Hanyu Pharmaceutical experienced a 5.02% increase in stock price, reaching 21.97 CNY per share, with a trading volume of 655 million CNY and a turnover rate of 4.05%, resulting in a total market capitalization of 19.405 billion CNY [1] - Hanyu Pharmaceutical, established on April 2, 2003, and listed on April 7, 2011, is located in Longhua District, Shenzhen, Guangdong Province, and primarily engages in chemical pharmaceuticals and medical devices, with 100% of its revenue derived from the pharmaceutical manufacturing sector [1] Group 2 - According to data from the top ten holdings of funds, one fund under China Merchants Fund holds Hanyu Pharmaceutical as a significant investment. The fund, China Merchants Stable Growth Mixed A (010503), reduced its holdings by 500 shares in the second quarter, maintaining a total of 500 shares, which represents 0.02% of the fund's net value, ranking it as the ninth largest holding [2] - The China Merchants Stable Growth Mixed A fund was established on February 5, 2021, with a latest scale of 23.4958 million CNY. Year-to-date returns are 1.7%, ranking 7700 out of 8226 in its category, while the one-year return is 2.11%, ranking 7599 out of 8099. Since inception, the fund has achieved a return of 0.77% [2] - The fund manager, Chen Jiarong, has a tenure of 16 years and 313 days, with total assets under management of 51.3802 million CNY. The best return during his tenure is 45.74%, while the worst return is -4.97% [2]

Core Points - Han Yu Pharmaceutical announced a financing plan to raise up to 700 million RMB from Shenzhen High-tech Investment Group and its subsidiaries [2] - The financing will cover multiple products and has a term of no more than 12 months [2] - The financing will be secured by assets from the company's Pingshan branch and Dali subsidiary [2]

Core Viewpoint - The company has approved a financing proposal to raise up to RMB 700 million from Shenzhen High-tech Investment Group Co., Ltd. and its subsidiaries, with a term not exceeding 12 months [1] Financing Details - The total financing amount is capped at RMB 700 million, covering multiple products [1] - The financing will be secured by collateral from the company's Pingshan branch and Dali subsidiary [1] - The specific terms will be finalized in the actual signed contract [1]

证券代码：300199 证券简称：翰宇药业 公告编号：2025-053 一、本次融资情况概述 深圳翰宇药业股份有限公司 关于向深圳市高新投集团有限公司及其 下属子公司融资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于 2025 年 10 月 21 日召开了第六届董事会第八次会议，审议通过了《关于向深圳市高新投集团有限 公司及其下属子公司融资的议案》。同意公司向深圳市高新投集团有限公司及其下 属子公司申请融资，融资总额不超过人民币 7 亿元，涵盖多个产品，期限不超过 12 个月，本次融资由公司坪山分公司及大理子公司部分资产进行抵押担保，上述内容 具体以实际签署的合同为准。 为保证本次融资顺利进行，提高融资效率，公司董事会授权公司董事长或授权 代表就相关文件签字或盖章，授权经营层根据资金需求情况在前述授信额度内使用。 二、相关方基本情况 公司名称：深圳市高新投集团有限公司 法定代表人：邵钢 注册资本：1592095.7914万元人民币 统一社会信用代码：914403001923012884 注册 ...